Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.29 USD | +4.57% | +10.10% | +30.11% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 143M |
---|---|---|---|---|---|
Net income 2024 * | -30M | Net income 2025 * | -45M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.77
x | P/E ratio 2025 * |
-4.2
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.74% |
Latest transcript on Corvus Pharmaceuticals, Inc.
1 day | +4.57% | ||
1 week | +10.10% | ||
Current month | +47.74% | ||
1 month | +62.41% | ||
6 months | +57.93% | ||
Current year | +30.11% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Miller
CEO | Chief Executive Officer | 73 | 14-01-26 |
Leiv Lea
DFI | Director of Finance/CFO | 70 | 14-01-26 |
James Rosenbaum
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Miller
CEO | Chief Executive Officer | 73 | 14-01-26 |
Ian Clark
BRD | Director/Board Member | 62 | 17-01-02 |
Terry Gould
BRD | Director/Board Member | 67 | 14-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 2.29 | +4.57% | 252,758 |
24-05-16 | 2.19 | -1.35% | 173,800 |
24-05-15 | 2.22 | -1.77% | 239,573 |
24-05-14 | 2.26 | +7.11% | 537,260 |
24-05-13 | 2.11 | +1.44% | 319,852 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.11% | 143M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- CRVS Stock